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Recent safety concerns regarding the newly introduced first-line 
HIV integrase inhibitor dolutegravir (DTG) have brought necessary 
attention to the need for pharmacovigilance during pregnancy and 
breastfeeding. In 2018, Botswana’s Tsepamo study[1] identified a 
signal of increased risk of neural tube defects (NTDs) in infants 
exposed to DTG periconception. This finding prompted a flurry of 
response in those countries where DTG is or will be a cornerstone 
of first-line antiretroviral regimens.[2] Previously, 12 years passed 
from the first case reports of suspected efavirenz teratogenicity to 
the acquisition of sufficient observational data to allay these fears.[3,4]
Pregnant women are increasingly exposed to medicines and 
vaccines. In the USA, more than 90% of women report taking at least 
one prescription or over-the-counter medicine during pregnancy.[5] 
In most cases the safety of these products in pregnancy is unknown. 
In Africa, women of child-bearing potential (WOCBP) are at the 
heart of the HIV, malaria and tuberculosis (TB) epidemics and are 
exposed to new medicines with limited data on safety in pregnancy.
South Africa (SA) will soon introduce DTG as part of first-
line antiretroviral therapy, with strong caution for WOCBP to 
use effective contraception, and will have the largest number of 
women using DTG in the world. Pregnancies will occur even if 
contraceptive services are enhanced. Determining whether the 
DTG risk signal is real or spurious requires ongoing collection 
of prospective data. To this end, prospective pregnancy exposure 
registries (PERs) are being developed at sentinel sites in the public 
sector. A PER was first implemented in the eThekwini district of 
KwaZulu-Natal (KZN) Province in 2013 and subsequently in the 
Klipfontein/Mitchell’s Plain subdistricts in Western Cape Province 
in 2016. Both sites adapted the World Health Organization (WHO)-
recommended approach of prospective data collection on exposures 
in a cohort of pregnant women from the first antenatal visit until 
the time of delivery.[6]
The National Institutes of Health-funded Tsepamo study 
in Botswana[1] similarly adapted WHO recommendations and 
included the following crucial elements to maximise validity and 
support causal inference: 
• Exposure data prospectively recorded throughout antenatal care 
(possibly captured later from the patient-held record)
• A control group of HIV-uninfected women, allowing for 
concurrent establishment of local background rates of congenital 
anomalies, including NTDs
• Exposures to non-default antiretroviral regimens, allowing for 
additional comparisons
• Surveillance embedded in routine antenatal and perinatal 
services, with data collected from routine clinical records
• Congenital malformations identified through standardised 
surface examinations on all live and stillbirths, verified (remotely) 
by a clinical geneticist, using photographs
• Independent of pharmaceutical industry involvement.
Ongoing monitoring and collection of information on additional 
exposures in the Botswana cohort have, reassuringly, failed to identify 
any additional cases.[7]
This approach facilitates the collection of all pharmaceutical 
exposures, affording the opportunity to assess the safety of other 
treatments commonly used in the same cohort of women (TB 
medicines, antiepileptics, vaccinations, etc.). It avoids the creation 
of research silos, establishing instead a platform for investigating 
the safety of medicines used by WOCBP, while restricting data 
elements to those collected as part of routine obstetric and neonatal 
care. It does, however, depend on quality care and clinical record 
keeping, which requires strengthening of these areas, particularly the 
recording of antenatal exposures and newborn surface examinations 
(including of stillbirths).
Regulatory actions
While awaiting further data, SA has made regulatory, clinical and 
policy recommendations on the use of DTG in WOCBP. In approving 
the registration of DTG-containing fixed-drug combinations, the South 
African Health Products Regulatory Authority (SAHPRA) mandated 
all manufacturers of DTG-based fixed-dose combinations to ensure 
that clinicians have access to reporting forms to refer all DTG-exposed 
pregnancies (regardless of outcome) to the international Antiretroviral 
Pregnancy Register (APR), an initiative that collates global pregnancy 
exposure case reports and compares and reports regularly on birth 
defect rates across antiretroviral therapy exposures. In addition, all 
suspected adverse reactions, particularly those not clearly reflected in 
the product information, must be reported to SAHPRA through its 
adverse reaction reporting system.[8] These are essential components 
of a more comprehensive risk management plan being implemented 
for DTG. More generally, SAHPRA will need to develop guidelines 
and tools to strengthen PERs to promote the effective monitoring of 
all health products.
Current status of PER projects in SA
Data generated by the existing PER projects will be an integral 
component of DTG safety monitoring. Combining the approaches 
of SAHPRA, the WHO and the APR registry will optimise the 
robustness of causality assessments.
Implementation of the PER, particularly in KZN, has been 
challenging. Uncertainties, lapses in funding, contention for political 
support in the face of competing priorities, and lack of record linkage 
capacity have hampered the generation of timely outputs. Many 
have called for less demanding alternative approaches, such as case 
detection of targeted congenital malformations or the establishment 
of a still poorly defined ‘national pregnancy register’. While all 
options need to be considered, whatever approach is selected must 
ensure that questions of drug safety in pregnancy can be answered 
with confidence and evidence accepted as valid by national and 
international policymakers.
To inform guidelines for the use of DTG in WOCBP, the National 
Department of Health has held consultations with clinicians, 
researchers, SAHPRA, the WHO, and civil society organisations 
representing the interests of women living with HIV. There was 
consensus that, while SA has centres of excellence, more needs to be 
done to build a network of sentinel PER sites across the country using 
the WHO approach. Above all, the PER projects should be nested 
within, and supported and informed by, the national maternal and 
child health programmes.
Urgent delivery of a more effective PER network in SA requires 
commitment, collaboration and investment from all stakeholders. 
Such support would include sustained political support, the 
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investment of national resources, and rigorous ethical and scientific 
review to ensure that the safety of priority health products is 
well understood, regardless of the impact of that information on 
treatment policies, economics and logistics. The benefits of such an 
initiative will extend far beyond addressing the DTG concerns, in 
pursuit of quality care for pregnant women and their infants.
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